Search

Your search keyword '"Davis, Megan M."' showing total 192 results

Search Constraints

Start Over You searched for: Author "Davis, Megan M." Remove constraint Author: "Davis, Megan M."
192 results on '"Davis, Megan M."'

Search Results

2. Need for Approval and Antisocial Behavior Moderate the Effect of Socioemotional Cues on Adolescent Girls' Cognitive Control

4. Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cells

6. Two cases of severe pulmonary toxicity from highly active mesothelin-directed CAR T cells

7. Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia

9. PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial

10. Neural Sensitivity to Peer Feedback and Depressive Symptoms: Moderation by Executive Function.

11. Decade-long leukaemia remissions with persistence of CD4+ CAR T cells

12. Author Correction: Decade-long leukaemia remissions with persistence of CD4+ CAR T cells

13. Diagnostic biomarkers to differentiate sepsis from cytokine release syndrome in critically ill children

14. Cognition-Emotion Interaction as a Predictor of Adolescent Depressive Symptoms

17. Deletion of the inhibitory co-receptor CTLA4 enhances and invigorates chimeric antigen receptor T cells

18. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma

21. BET bromodomain protein inhibition reverses chimeric antigen receptor extinction and reinvigorates exhausted T cells in chronic lymphocytic leukemia

23. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia

24. Supplemental Data from Reducing Ex Vivo Culture Improves the Antileukemic Activity of Chimeric Antigen Receptor (CAR) T Cells

25. Data from Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer

26. Data from Reducing Ex Vivo Culture Improves the Antileukemic Activity of Chimeric Antigen Receptor (CAR) T Cells

27. Supplemental Information and Legends from Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer

28. Supplemental Table S1 from Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer

29. Figures S1 - S5 from Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer

30. sTable 1, sTable 2, sTable 3, sFigure 1, sFigure 2, sFigure 3, sFigure 4 from The Safety of Bridging Radiation with Anti-BCMA CAR T-Cell Therapy for Multiple Myeloma

32. Author Correction: Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia

34. Interleukin-18 Secreting Autologous Anti-CD19 CAR T-Cells (huCART19-IL18) in Patients with Non-Hodgkin Lymphomas Relapsed or Refractory to Prior CAR T-Cell Therapy

35. BLIMP1 and NR4A3 transcription factors reciprocally regulate antitumor CAR T cell stemness and exhaustion

39. Abstract 5571: Disruption of cell-intrinsic checkpoint regulator CTLA-4 in CD19 directed CAR T cells provides clinical efficacy in CLL patients

40. The Safety of Bridging Radiation with Anti-BCMA CAR T-Cell Therapy for Multiple Myeloma

41. Decade-Long Remissions of Leukemia Sustained By the Persistence of Activated CD4+ CAR T-Cells

42. Humanized CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells in CAR-Naive and CAR-Exposed Children and Young Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia

43. Decade-long remissions of leukemia sustained by the persistence of activated CD4+ CAR T-cells

48. CRISPR-engineered T cells in patients with refractory cancer

Catalog

Books, media, physical & digital resources